Register
Annals of oncology : official journal of the European Society for Medical Oncology 2022 Mar 14
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.   

Related Questions

What adjuvant systemic therapy would you give a patient with ER+/HER2- breast cancer following ALND of pN2 nodal relapse after initial mastectomy, adjuvant TC, and adjuvant 5 years of endocrine therapy?
New comment by Medical Oncologist at NYU Winthrop Hospital ( May 11, 2024)
CALOR is an old trial, ER-neg patients benefited from chemotherapy, not ER-positive patients. Before NGS/PET scans were available. Now we have better tools for diagnosis and...
What endocrine therapy would you recommend to a premenopausal female with early stage HR+ Breast cancer who is transitioning from female to male and currently on testosterone?
New comment by Medical Oncologist at Oregon Health & Science University ( May 2, 2024)
I have had the opportunity to care for a few trans and transitioning people in this scenario and have approached it in the same fashion. In all cases, they chose b/l mastectom...
Copyright © 2024 theMednet
All Rights Reserved.